No Detail Found!

Genetics of metabolic disorders: Systematic assessment of clinicopathological role of GBA and HEXA mutations in Gaucher and Tay-Sachs Disease

Author(s)
Raima Kalhoro Departments of Pathology, People’s University of Medical and Health Sciences, Pakistan
Soobia Pathan Liaquat Institute of Medical and Health Sciences, Pakistan
Abdul Rehman Khalil Shaikh LUMHS, Jamshoro, Pakistan
Mohammad Shakeel New Lasani Medical Complex, Institute of Chemistry, Pakistan
Taleeha Roheen University of Sargodha, Pakistan
Sami Ali Babekir Ali Disability Research Center, Al-Neelain University, Soudan
Abstract
Objective: To investigates the genetic origins of Gaucher and Tay-Sachs disorders by examining GBA and HEXA gene mutations in relation to disease development, diagnostic methods, and therapeutic strategies. Methodology: This study followed the PRISMA 2020 guidelines and reviewed articles published between January 2023 until February 2024 using a systematic approach. The relevant articles were identified through PubMed, ScienceDirect, and other major databases, primarily focusing on genetic mutations, their pathological impact, clinical presentation, and treatment options. The initial review of 89 articles yielded 30 relevant studies, 11 were further examined for genetic pattern analysis, genotype-phenotype correlations, and recent treatment breakthroughs. The risk biases of studies were assessed using the Cochrane Risk of Bias tool. Results: The review showed that different mutations in the GBA and HEXA genes result in symptoms of Gau- cher disease and Tay-Sachs disease. The progress in genetic testing along with enzyme therapy improvem- ents, has brought significant benefits to patient outco- mes, although limitations in detection methods and the- rapy accessibility persist. Conclusion: Healthcare professionals now use disco- veries of GBA and HEXA mutations to detect early signs of genetic disorders, which support increased chances for targeted medical interventions. Additional research is required because advanced diagnostic instruments and innovative therapeutic solutions need to be deve- loped for treating complex illnesses.
Publication Details
Page(s) 804-808
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 50, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
metabolic disorders, HEXA mutation, GBA mutation, Tay-Sachs disease, genotype-phenotype cor- relation, Gaucher disease.
References
Rodrigues KF,Yong WTL,Bhuiyan MSA,Siddiquee S,Shah MD .2022 .Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review. Biology, 11 : 1308-12.
Collin-Histed T,Rosenberg A,Hopman N,Pacey J .2023 .Understanding patient and parent/caregiver perceptions on gene therapy in Gaucher disease: an international survey. Orphanet J Rare Dis, 18 : 5-9.
Roh J,Subramanian S,Weinreb NJ,Kartha RV .2022 .Gaucher disease - more than just a rare lipid storage disease. J Mol Med, 100 : 499-518.
Flotte TR,Cataltepe O,Puri A,Batista AR,Moser R,McKenna-Yasek D .2022 .AAV gene therapy for Tay-Sachs disease. Nat Med, 28 : 251-9.
Daykin EC,Ryan E,Sidransky E. .2021 .Diagnosing neuronopathic Gaucher disease: new considerations and challenges in assigning Gaucher phenotypes. Mol Genet Metab, 132 : 49-58.
Hussein N,Henneman L,Kai J,Qureshi N. .2021 .Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis, and Tay-Sachs disease. Cochrane Database Syst Rev, 10 : CD010849.
Marchetti M,Faggiano S,Mozzarelli A .2022 .Enzyme Replacement Therapy for Genetic Disorders Associated with Enzyme Deficiency. Curr Med Chem, 29 : 489-525.
Desnick RJ,Schuchman EH .2002 .Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet, 3 : 954-66.
Vairo F,Netto C,Dorneles A,Mittelstadt S,Wilke M,Doneda D .2013 .Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment. JIMD Rep, 11 : 1-6.
Phetthong T,Tim-Aroon T,Khongkraparn A,Noojarern S,Kuptanon C,Wichajarn K .2021 .Gaucher disease: clinical phenotypes and refining GBA mutational spectrum in Thai patients. Orphanet J Rare Dis, 16 : 519-23.
Bibi F,Ullah A,Bourinaris T,Efthymiou S,Kriouile Y,Sultan T .2021 .Tay-Sachs Disease: Two Novel Rare HEXA Mutations from Pakistan and Morocco. Klin Padiatr, 233 : 226-230.
Mistri M,Tamhankar PM,Sheth F,Sanghavi D,Kondurkar P,Patil S .2012 .Identification of novel mutations in HEXA gene in children affected with Tay Sachs disease from India. PLoS One, 7(6) : e39122.
Hughes DA,Deegan P,Giraldo P,Göker-Alpan Ö,Lau H,Lukina E .2022 .Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J Clin Med, 11 : 5158-63.
Greuel A,Trezzi JP,Glaab E,Ruppert MC,Maier F,Jäger C .2020 .GBA variants in Parkinson's disease: clinical, metabolomic, and multimodal neuroimaging phenotypes. Movem Disord, 35 : 2201-10.
Lefter S,Mahony O,Sweeney O,Ryan B,AM B .2020 .Late-Onset Tay-Sachs Disease in an Irish Family. Mov Disord Clin Pract, 8 : 106-110.
Zhang X,Wu Y,Wang L,Wu Q,Liu Q,Li R .2023 .. Clinical Characteristics and GBA Gene Mutation Analysis of Gaucher Disease Type I. Clin Lab, 69 : 837-42.
Darling A,Irún P,Giraldo P,Armstrong J,Gort L,DíazConradi Á .2021 .Pediatric Gaucher disease with intermediate type 2-3 phenotype associated with parkinsonian features and levodopa responsiveness. Parkinsonism Relat Disord, 91 : 19-22.
Bilyalova A,Shagimardanova E,Bilyalov A,Zaripova M,Shigapova L,Gazizova G .2024 .Novel Hex A splice site mutations in a patient with late atypical onset Tay-Sachs disease: importance of combined NGS and biochemical analysis. Front Neurol, 15 : 1400989.
Istaiti M,Revel‐Vilk S,Becker‐Cohen M,Dinur T,Ramaswami U,Castillo‐Garcia D .2021 .Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. Am J Hematol, 96 : 545-51.
Park JH,Ko JM,Kim MS,Kim MJ,Seong MW,Yoo T .2021 .Novel HEXA variants in Korean children with TaySachs disease with regression of neurodevelopment from infancy. Mol Genet Genomic Med, 9 : e1677.
Dubiela P,Szymanska-Rozek P,Hasinski P,Lipinski P,Kleinotiene G,Giersz D,Short-Term Glucosphingosine D .2024 .lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy. Biomolecules, 14 : 842-7.
Sagaser KG,Malinowski J,Westerfield L,Proffitt J,Hicks MA,Toler TL .2023 .Expanded carrier screening for reproductive risk assessment: An evidence-based practice guideline from the National Society of Genetic Counselors. J Genet Couns, 32 : 540-557.
Lin Y,Zhao X,Liou B,Fannin V,Zhang W,Setchell KDR .2024 .Intrinsic link between PGRN and Gba1 D409V mutation dosage in potentiating Gaucher disease. Hum Mol Genet, 33 : 1771-88.
Eskes ECB,Beishuizen CRL,Corazolla EM,van Middelaar T,Brands MMMG,Dekker H .2022 .Patients' view on gene therapy development for lysosomal storage disorders: a qualitative study. Orphanet J Rare Dis, 17 : 383-7.
0

Citations

0

Downloads

50

Views